News & Articles

In a 17-4 vote, the FDA vaccine advisory committee recommended that Pfizer/BioNTech’s COVID-19 vaccine should be distributed to the U.S.

Parties to collaborate on development, commercialization, and supply of the Orgenesis therapies pipeline

Here’s what you should know when choosing the best bottles for your cell culture experiment

The kit is ideally suited to NGS library preparation from a low input, patient-derived sample types, such as nasal swabs

The new technology incorporates a 3D sensor to provide volumetric measurement to assess the integrity of a range of pharmaceutical solid dose

Designed to enrich pathologists' skills in biomarker interpretation and scoring techniques

The assay is developed for use in detection, characterisation, and monitoring of the SARS-CoV-2 virus

Watch world-leading scientists and industry experts present the latest advances and emerging trends in biopharma, online December 8-10

Access SARS-CoV-2 IgG II test is a semi-quantitative assay that measures patient’s relative level of antibodies in response to a previous SARS-CoV-2 infection

Susie Harborth explores what it takes to be a scientist entrepreneur and highlights the technology driving innovation in bioscience

Two different dosing regimens demonstrated efficacy with one showing a better profile

Observations of rapid recovery on chest x-rays noted and no drug-related Serious Adverse Events reported

The new lots further enhance Lonza’s renowned human primary cell offerings as it looks to meet growing market demand for deeper cell characterization

In this webinar Aaron Hineman, PerkinElmer, will review a total ICP-MS solution for your pharmaceutical impurity testing needs

Test adds to QIAGEN’s growing portfolio of PCR testing solutions for COVID-19 testing

Join scientists from across the globe to explore the latest developments in biopharma, from new research techniques to cutting-edge technologies and resources to advance your work

QIAreach SARS-CoV-2 Antigen Test is an important step towards decentralized mass screening by processing samples in 2–15 minutes

Phase 3 part of clinical trial to enrol over 30,000 volunteers worldwide

The kit promises to be a low cost, high-sensitivity diagnostic test for COVID-19 detection

Collaboration to develop next-generation CAR-T cell therapies with improved efficacy and durability

The new IgM antibody test demonstrated 99.9% specificity with 1,400 negative samples and 100% sensitivity at >18 days post symptom onset and post positive PCR

Underscores importance of serological testing using the S1 subunit for worldwide seroprevalence and vaccine development